Article: Epigenomics AG Announces End of IPO Lock-Up Period.

Original VC Investors Indicate Continued Support of Company

Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that it has been informed by the majority of its venture capital investors:

 
  - DVC (DVCG mbH & Co Fonds II KG, Venture Capital mbH & Co Fonds III), 
 
  - MPM (MPM Bioventures GmbH & Co; MPM Bioventures II-QP, LP; MPM 
Bioventures II, LP; MPM Asset Management Investors 2000 BLLC), 
 
  - 3i (Technologie Holding Fonds VC GmbH; 3i Group Investments LPM; 
Technologieholding Fonds NBL GmbH), 
 
  - Strategic European Technologies NV, 
 
  - Abingworth (Abingworth ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!